If 13D really wanted to get my attention with their "advancingLeronlimab" team then they need to present a pathway to profit with some real meat. We all know that LL will be approved eventually even if our current team is getting a tough lesson in the learing curve. Even so thats a "bird in the hand" that sings a song we know. 13D needs a better pitch than we can do the same thing better.

Heres what would get me thinking... Come with an offer sheet from a consortium or BP ( they can be nameless for now but needs to be a signed contract ) showing how much they are willing to pay outright or in royalties for each indication as it is approved. To me for existing CYDY shareholer I would expect 25 -75 billion depending on approvals and commercial success but a minimum of 15 billion up front.
Now i would be interested other wise go away